Apogee Therapeutics Inc. (APGE)
(Real Time Quote from BATS)
$50.16 USD
-0.04 (-0.07%)
Updated Jul 23, 2024 01:30 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
APGE 50.16 -0.04(-0.07%)
Will APGE be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for APGE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for APGE
Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why
APGE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for APGE
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
NewAmsterdam Pharma appoints McKenna, Joustra to board of directors
Apogee Therapeutics: Infrequent Dosing Advantage In Biotech Play
Apogee Therapeutics intiated with Not Rated at Goldman Sachs
Buy Rating for Apogee Therapeutics: Promising Prospects for Dupixent and APG808 in COPD Market